Solu-Medrol (methylprednisolone) for Multiple Sclerosis

Solu-Medrol (methylprednisolone) is a corticosteroid with anti-inflammatory action. It is used to treat acute exacerbations in patients with multiple sclerosis (MS). Solu-Medrol can also be used for several other diseases. This drug can be administered via intravenous or intramuscular routes.

How Solu-Medrol works

Solu-Medrol has a powerful, complex anti-inflammatory method of action that is still being studied.

A 2005 publication states that the reduction of the inflammatory cycle is related to several actions at the same time: dampening the inflammatory cytokine cascade; inhibiting the activation of T-cells; decreasing the extravasation of immune cells into the central nervous system; facilitating the death of activated immune cells; and indirectly decreasing the cytotoxic effects of nitric oxide and tumor necrosis factor alpha.

Understanding Solu-Medrol’s mechanism of action is a crucial step in developing more specific treatments for multiple sclerosis.

Adverse reactions include allergic reactions; blood and lymphatic system disorders; and problems with cardiovascular, dermatologic, endocrine, gastrointestinal, hepatobiliary, metabolic, neurological and ophthalmic systems.problems.

Clinical trials for Solu-Medrol

A double-blind study of high-dose methylprednisolone versus a placebo showed that after three to six days of therapy, some signs of improvement were related to a marked decrease in the rate of central nervous system (CNS) IgG synthesis. CNS IgG production slowly returned toward baseline despite progressive clinical improvement.

Another trial consisted of a double-blind, placebo-controlled trial of high-dose, intravenous methylprednisolone in 50 individuals with multiple sclerosis; 22 patients were in acute relapse and 28 had chronic progressive disease. This study showed that among the patients with relapse, there was a significant decrease in clinical disability scores at one and four weeks in the methylprednisolone treated group compared with controls.

In the chronic progressive MS group, disability scores were significantly lower after four weeks of treatment with methylprednisolone, attributed to improvement in motor coordination.

The usual dosage of Solu-medrol is 500 to 1,000 mg, administered daily via intravenous route. It can be administered with or without oral steroids.

Several studies compared the efficiency of the intravenous route to the oral route. One study of 25 patients with an exacerbation of MS lasting less than four weeks were randomized to receive methylprednisolone or a placebo treatment. This trial showed that high-dose methylprednisolone is recommended to manage MS exacerbations. Other studies aimed to determine a more comfortable administration of the treatment to the patient.

Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These flash briefings give our readers an alternative option for accessing information important for them.

Listen Here